Missionirnewsbreaks Silo Pharma Inc. (NASDAQ: SILO) To Participate In IPAC-RS 2026 Nasal Innovation Forum

(MENAFN- Investor Brand Network) Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, announced that company representatives will participate in the IPAC-RS 2026 Nasal Innovation Forum, taking place Sept. 16-17, 2026, in Jersey City, New Jersey. CEO Eric Weisblum said the forum provides an opportunity to engage with experts in nasal drug development as Silo continues advancing SPC-15's novel nose-to-brain approach to targeted drug delivery for the treatment of PTSD. Preclinical data showed that the SPC-15 formulation and device met predefined specifications for assay, impurities, pH and microbiological quality through nine months, while six-month accelerated stability data was consistent and aligned with long-term data.

To view the full press release, visit

About Silo Pharma, Inc.

Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories. silopharma

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company's newsroom at

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: imer, class="wp-block-paragraph">MissionIR
Austin, Texas

512.354.7000 Office
href="/cdn-cgi/l/email-protection#ebae8f829f8499aba6829898828485a2b9c5888486" target="_blank" rel="noreferrer noopener">[email protected]

MissionIR is powered by IBN

MENAFN09092026000224011066ID1111643035